(Total Views: 673)
Posted On: 05/22/2024 10:23:22 PM
Post# of 148870
What do you think the first catalyst will be that is announced ?
My guess is partnership for pilot study in Alzheimer's Disease patients.
March 5, 2024 investor call:
Dr. Jay in the 3/5 webcast:
“I would also like to note the growing body of evidence implicating the role of inflammation, and specifically CCR-five in the pathogenesis of Alzheimer's disease. This is obviously an area of enormous and urgent unmet needs. And given the [well tolerated] safety profile of LeronLimab to date, together with data from a recent preclinical study suggesting that blocking CCR5 in mice can rescue memory deficits. I believe a pilot study in patients with Alzheimer's disease is now justified.”
May 16, 2024 Letter to Shareholders:
"We have identified several such opportunities that we believe are intriguing, and anticipate finalizing agreements with these partners in the very near future. Such potential partnerships include an investigator-initiated pilot study of leronlimab in patients with Alzheimer’s Disease"
My guess is partnership for pilot study in Alzheimer's Disease patients.
March 5, 2024 investor call:
Dr. Jay in the 3/5 webcast:
“I would also like to note the growing body of evidence implicating the role of inflammation, and specifically CCR-five in the pathogenesis of Alzheimer's disease. This is obviously an area of enormous and urgent unmet needs. And given the [well tolerated] safety profile of LeronLimab to date, together with data from a recent preclinical study suggesting that blocking CCR5 in mice can rescue memory deficits. I believe a pilot study in patients with Alzheimer's disease is now justified.”
May 16, 2024 Letter to Shareholders:
"We have identified several such opportunities that we believe are intriguing, and anticipate finalizing agreements with these partners in the very near future. Such potential partnerships include an investigator-initiated pilot study of leronlimab in patients with Alzheimer’s Disease"
(5)
(0)Scroll down for more posts ▼
